AWM
GSK icon

Aberdeen Wealth Management’s GSK GSK Stock Holding History

Aberdeen Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,110
Closed -$210K – 138
2020
Q2 		$210K Buy
+4,110
New +$211K 0.23% 116
2020
Q1 		– Sell
-4,007
Closed -$235K – 128
2019
Q4 		$235K Buy
+4,007
New +$223K 0.18% 126

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Aberdeen Wealth Management's GSK Position: Q3 2020 in Review

Aberdeen Wealth Management sold out of GSK (GSK) in Q3 2020, closing a stake of 4,110 shares — an estimated $210K sold.

Aberdeen Wealth Management first reported a position in GSK in Q4 2019 and held it in 2 quarters. The position peaked at $235K in Q4 2019. 826 funds tracked by Wall St. Rank hold GSK as of Q3 2020.

  • Aberdeen Wealth Management reported no remaining GSK position as of Q3 2020 after selling out during the quarter.
  • Aberdeen Wealth Management sold 4,110 GSK shares in Q3 2020, an estimated $210K.
  • Aberdeen Wealth Management first reported a position in GSK in Q4 2019 and held it in 2 quarters.
  • Aberdeen Wealth Management's GSK position peaked at $235K in Q4 2019.
  • 826 funds tracked by Wall St. Rank held GSK as of Q3 2020.

Based on Aberdeen Wealth Management's 13F filing for Q3 2020, filed 13 Nov 2020.